# Tandem Diabetes Care Inc: overview

TNDM · Nasdaq · CIK 1438133 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tndm.md) · [Financials](/companies/tndm/financials.md) · [Filings](/companies/tndm/filings.md) · [Insiders](/companies/tndm/insiders.md)

Latest reported revenue: [$254.6m](/filings/0001438133-26-000125.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001438133-26-000125).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [244](/filings/0001438133-25-000187.md) | [283](/filings/0001438133-26-000010.md) | [234](/filings/0001438133-26-000049.md) | [241](/filings/0001438133-26-000125.md) | [249](/filings/0001438133-25-000187.md) | [290](/filings/0001438133-26-000010.md) | [247](/filings/0001438133-26-000049.md) | [255](/filings/0001438133-26-000125.md) |
| Gross margin | % | [51.1%](/filings/0001438133-25-000187.md) | [55.7%](/filings/0001438133-26-000010.md) | [50.5%](/filings/0001438133-26-000049.md) | [52.3%](/filings/0001438133-26-000125.md) | [53.9%](/filings/0001438133-25-000187.md) | [57.7%](/filings/0001438133-26-000010.md) | [55.3%](/filings/0001438133-26-000049.md) | [56.9%](/filings/0001438133-26-000125.md) |
| Operating margin | % | [(10.7%)](/filings/0001438133-25-000187.md) | [(0.2%)](/filings/0001438133-26-000010.md) | [(51.6%)](/filings/0001438133-26-000049.md) | [(21.5%)](/filings/0001438133-26-000125.md) | [(9.2%)](/filings/0001438133-25-000187.md) | [2.9%](/filings/0001438133-26-000010.md) | [(7.1%)](/filings/0001438133-26-000049.md) | [(5.4%)](/filings/0001438133-26-000125.md) |
| Net margin | % | [(9.5%)](/filings/0001438133-25-000187.md) | [0.3%](/filings/0001438133-26-000010.md) | [(55.7%)](/filings/0001438133-26-000049.md) | [(21.8%)](/filings/0001438133-26-000125.md) | [(8.5%)](/filings/0001438133-25-000187.md) | [(0.2%)](/filings/0001438133-26-000010.md) | [(8.2%)](/filings/0001438133-26-000049.md) | [(8.3%)](/filings/0001438133-26-000125.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001438133-25-000187.md) | [0.01](/filings/0001438133-26-000010.md) | [(1.97)](/filings/0001438133-26-000049.md) | [(0.78)](/filings/0001438133-26-000125.md) | [(0.31)](/filings/0001438133-25-000187.md) | [(0.01)](/filings/0001438133-26-000010.md) | [(0.30)](/filings/0001438133-26-000049.md) | [(0.31)](/filings/0001438133-26-000125.md) |
| Free cash flow | $m | [21.5 d](/filings/0001438133-25-000187.md) | [7.6 d](/filings/0001438133-26-000010.md) | [(21.2)](/filings/0001438133-26-000049.md) | [(15.7) d](/filings/0001438133-26-000125.md) | [4.2 d](/filings/0001438133-25-000187.md) | [3.1 d](/filings/0001438133-26-000010.md) | [4.8](/filings/0001438133-26-000049.md) | [(38.7) d](/filings/0001438133-26-000125.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [703](/filings/0001438133-24-000028.md) | [801](/filings/0001438133-25-000036.md) | [748](/filings/0001438133-26-000010.md) | [940](/filings/0001438133-26-000010.md) | [1,015](/filings/0001438133-26-000010.md) |
| Gross margin | % | [53.5%](/filings/0001438133-24-000028.md) | [51.5%](/filings/0001438133-25-000036.md) | [49.2%](/filings/0001438133-26-000010.md) | [52.1%](/filings/0001438133-26-000010.md) | [53.8%](/filings/0001438133-26-000010.md) |
| Operating margin | % | [3.2%](/filings/0001438133-24-000028.md) | [(11.6%)](/filings/0001438133-25-000036.md) | [(31.2%)](/filings/0001438133-26-000010.md) | [(10.5%)](/filings/0001438133-26-000010.md) | [(18.5%)](/filings/0001438133-26-000010.md) |
| Net margin | % | [2.2%](/filings/0001438133-24-000028.md) | [(11.8%)](/filings/0001438133-25-000036.md) | [(29.8%)](/filings/0001438133-26-000010.md) | [(10.2%)](/filings/0001438133-26-000010.md) | [(20.2%)](/filings/0001438133-26-000010.md) |
| Diluted EPS | $ per share | [0.24](/filings/0001438133-24-000028.md) | [(1.47)](/filings/0001438133-25-000036.md) | [(3.43)](/filings/0001438133-26-000010.md) | [(1.47)](/filings/0001438133-26-000010.md) | [(3.04)](/filings/0001438133-26-000010.md) |
| Free cash flow | $m | [97.2](/filings/0001438133-24-000028.md) | [16.4](/filings/0001438133-25-000036.md) | [(58.6)](/filings/0001438133-26-000010.md) | [5.0](/filings/0001438133-26-000010.md) | [(29.7)](/filings/0001438133-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tndm/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Twomey Christopher J](/insiders/1238935.md) | Director | Sale (S) | 1,700 | $19.15 | $32.6k | [Form 4](/filings/0001438133-26-000136.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $174.8m | 11,583,125 |  | Added +892,281 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $78.1m | 5,178,570 | Call | Unchanged |
| [Sessa Capital IM, L.P.](/funds/1595849.md) | 2026-06-30 | $77.0m | 5,100,000 |  | Added +369,243 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $64.9m | 4,299,667 |  | Added +306,334 |
| [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $51.1m | 3,383,553 |  | Added +2,068,838 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $46.7m | 3,096,536 |  | Added +57,617 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $43.0m | 2,851,646 |  | Added +189,386 |
| [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $35.2m | 2,331,429 |  | Added +672,981 |
| [Paradice Investment Management LLC](/funds/1620275.md) | 2026-06-30 | $30.5m | 2,024,014 |  | Reduced −18,411 |
| [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $30.3m | 2,006,429 |  | Added +482,483 |

## Recent filings

[All 1,251 filings](/companies/tndm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:11 ET | [10-Q](/filings/0001438133-26-000125.md) | Quarterly report, period 2026-06-30 | 0001438133-26-000125 |
| 2026-08-06 | 16:08 ET | [8-K](/filings/0001438133-26-000124.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438133-26-000124 |
| 2026-05-21 | 16:10 ET | [8-K](/filings/0001438133-26-000070.md) | 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001438133-26-000070 |
| 2026-05-15 | 07:59 ET | [8-K](/filings/0001438133-26-000052.md) | 5.02 Departure or appointment of officers or directors | 0001438133-26-000052 |
| 2026-05-07 | 16:06 ET | [10-Q](/filings/0001438133-26-000049.md) | Quarterly report, period 2026-03-31 | 0001438133-26-000049 |
| 2026-05-07 | 16:02 ET | [8-K](/filings/0001438133-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438133-26-000048 |
| 2026-04-07 | 16:23 ET | [DEF 14A](/filings/0001438133-26-000034.md) | Proxy statement, period 2025-12-31 | 0001438133-26-000034 |
| 2026-02-27 | 16:06 ET | [8-K](/filings/0001140361-26-007142.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-007142 |
| 2026-02-19 | 16:09 ET | [10-K](/filings/0001438133-26-000010.md) | Annual report, period 2025-12-31 | 0001438133-26-000010 |
| 2026-02-19 | 16:06 ET | [8-K](/filings/0001438133-26-000009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438133-26-000009 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001438133-26-000010.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/79f02546-c355-44fd-9ddb-7c34c3e49589)

## About the filer

- CIK: 1438133
- Tickers: TNDM
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:09 ET. No prices; not investment advice.